-

Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Jefferies 2020 Healthcare Conference on June 2, 2020 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.

A live audio webcast and archive of the presentation will be available in the Investors & Media section of the company website at ir.mirumpharma.com.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit mirumpharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

Contacts

Investor contact:
Ian Clements, Ph.D.
ir@mirumpharma.com

Media contact:
Erin Murphy
media@mirumpharma.com

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Release Summary
Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
Release Versions

Contacts

Investor contact:
Ian Clements, Ph.D.
ir@mirumpharma.com

Media contact:
Erin Murphy
media@mirumpharma.com

More News From Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026...

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026...

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026...
Back to Newsroom